After reporting that it has halted trials of its most advanced cancer drug,shares in Juno Therapeutics (NASDAQ: JUNO) lost 57.1% of their value in 2016, according toS&P Global Market Intelligence.

The Weeknd dominated the 2016 JUNO Awards in Calgary tonight, taking home a total of five trophies, including Artist Of The Year, Single Of The Year, and Album Of The Year. No one came close to Abel's ...

Juno Therapeutics (ticker: JUNO) stock soared on Wednesday, a day after the biopharmaceutical company was granted permission by the U.S. Food and Drug Administration to continue a phase II clinical ...

Juno is pushing ahead with an effort to get its cancer drug developed and commercialized globally. Celgene will take on that job, paying Juno $50 million in cash for ...

Setback opens the window for competitor Kite Pharma Inc. Seattle-based Juno Therapeutics reaffirmed yesterday in a new SEC filing that Federal Drug Administration approval of its drug will not happen ...